{"id":"W4403410406","doi":"10.1016/j.jtho.2024.09.026","title":"OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Samsung; Université de Versailles Saint-Quentin-en-Yvelines; Sir Run Run Shaw Hospital; Faculty of Medicine, Prince of Songkla University; Deutsches Zentrum für Lungenforschung; College of Medicine, Seoul National University; Seoul National University Bundang Hospital; Prince of Songkla University; Institut Gustave-Roussy; Yonsei University College of Medicine; McGill University; Baskent Üniversitesi; Shanghai Jiao Tong University; Royal Marsden NHS Foundation Trust; Kindai University; Zhejiang University; Sungkyunkwan University; Yonsei University; Deutsches Krebsforschungszentrum; Capital Medical University; Seoul National University; Zhengzhou University; City of Hope; Kanazawa University; Nationales Centrum für Tumorerkrankungen Heidelberg; Universitätsklinikum Heidelberg; Hospital de Câncer de Barretos; Shanghai Chest Hospital","keywords":"Osimertinib; Medicine; Oncology; Mutant; First line; Second line; Internal medicine; Line (geometry); Epidermal growth factor receptor; Genetics; Cancer; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002246867,0.001099793,0.002892458,0.0003675568,0.0004133372,0.002472982,0.0007719061,0.001237741,0.002664395],"category_scores_gemma":[0.002208973,0.0005936499,0.005682834,0.0007762638,0.0005729015,0.001739981,0.0005666675,0.003265841,0.0006641247],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001154,"about_ca_system_score_gemma":0.001012986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002532986,"about_ca_topic_score_gemma":0.005042973,"domain_scores_codex":[0.9990618,0.0002919868,0.00008374167,0.0002298649,0.00009073105,0.0002418662],"domain_scores_gemma":[0.9987898,0.0002586639,0.0003477775,0.0001799427,0.00008369541,0.0003400448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8211441,0.0028166,0.06943143,0.001113305,0.01950849,0.0004167312,0.0002107138,0.001812117,0.006735349,0.0004726795,0.003243473,0.07309496],"study_design_scores_gemma":[0.2314725,0.139156,0.5459464,0.000782677,0.05975772,0.0009993927,0.0007725478,0.003857658,0.002707732,0.001735903,0.0125463,0.0002652602],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839977,0.01169918,0.0001774276,0.0004879912,0.000354154,0.00008878967,0.001156441,0.00002626611,0.002012054],"genre_scores_gemma":[0.9924641,0.003215298,0.0001413412,0.0006367668,0.000388206,0.00008732307,0.001741027,0.00001690841,0.001309106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002892458,"threshold_uncertainty_score":0.01188272,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02226847041822816,"score_gpt":0.4249221548174373,"score_spread":0.4026536843992092,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}